ES2533788T3 - Compuestos inhibidores de PI3K de tipo purina y métodos de uso - Google Patents

Compuestos inhibidores de PI3K de tipo purina y métodos de uso Download PDF

Info

Publication number
ES2533788T3
ES2533788T3 ES09755767.2T ES09755767T ES2533788T3 ES 2533788 T3 ES2533788 T3 ES 2533788T3 ES 09755767 T ES09755767 T ES 09755767T ES 2533788 T3 ES2533788 T3 ES 2533788T3
Authority
ES
Spain
Prior art keywords
morpholino
purin
alkylene
methyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09755767.2T
Other languages
English (en)
Spanish (es)
Inventor
Georgette Castanedo
Irina Chuckowree
Adrian Folkes
Daniel P. Sutherlin
Nan Chi Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2533788T3 publication Critical patent/ES2533788T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09755767.2T 2008-05-30 2009-05-29 Compuestos inhibidores de PI3K de tipo purina y métodos de uso Active ES2533788T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57559 1987-06-03
US5755908P 2008-05-30 2008-05-30
PCT/US2009/045603 WO2009146406A1 (en) 2008-05-30 2009-05-29 Purine pi3k inhibitor compounds and methods of use

Publications (1)

Publication Number Publication Date
ES2533788T3 true ES2533788T3 (es) 2015-04-14

Family

ID=41017038

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09755767.2T Active ES2533788T3 (es) 2008-05-30 2009-05-29 Compuestos inhibidores de PI3K de tipo purina y métodos de uso

Country Status (14)

Country Link
US (2) US8158624B2 (enExample)
EP (1) EP2279188B1 (enExample)
JP (1) JP2011521968A (enExample)
KR (1) KR20110042153A (enExample)
CN (1) CN102105474B (enExample)
AU (1) AU2009251291B2 (enExample)
BR (1) BRPI0909614A2 (enExample)
CA (1) CA2721851A1 (enExample)
ES (1) ES2533788T3 (enExample)
IL (1) IL208838A0 (enExample)
MX (1) MX2010012583A (enExample)
RU (1) RU2509081C2 (enExample)
WO (1) WO2009146406A1 (enExample)
ZA (1) ZA201007524B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
CN101835779B (zh) * 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
US8754080B2 (en) 2009-04-03 2014-06-17 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (S) inhibitors
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
SG175708A1 (en) * 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG182247A1 (en) * 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US8828990B2 (en) * 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
CN102711766B (zh) * 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CA2802808A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use
AU2011302124B2 (en) 2010-09-14 2016-03-17 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
AU2011343712B2 (en) * 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
MX347708B (es) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
CN104010494B (zh) * 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
HK1199725A1 (en) 2011-08-29 2015-07-17 无限药品股份有限公司 Heterocyclic compounds and uses thereof
PT2771342T (pt) * 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
US20150011569A1 (en) * 2011-12-15 2015-01-08 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104350144B (zh) 2012-05-23 2017-08-04 弗·哈夫曼-拉罗切有限公司 获得和使用内胚层和肝细胞的组合物和方法
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
CN103936742B (zh) * 2013-01-17 2017-05-03 程鹏 含嘌呤基的新型pi3k抑制剂及其制备方法和应用
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
RS57461B1 (sr) * 2013-05-02 2018-09-28 Hoffmann La Roche Derivati purina kao agonisti cb2 receptora
WO2014185367A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 モルホリノプリン誘導体の製造方法
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104557872B (zh) * 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
CN103804380B (zh) * 2014-01-24 2016-05-18 温州医科大学 以IKK-β为靶点的2-氨基-8-取代鸟嘌呤衍生物、应用及其制备方法
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015188369A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN107205923B (zh) * 2014-12-17 2021-03-05 辉瑞大药厂 用于静脉内给药的pi3k/mtor-抑制剂的制剂
PT3277682T (pt) 2015-03-30 2019-07-09 Daiichi Sankyo Co Ltd Derivados de 6-morfolinil-2-pirazolil-9h-purina e utilização dos mesmos como inibidores de pi3k
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
EA033106B1 (ru) * 2015-04-21 2019-08-30 Гуйчжоу Бэйлинг Груп Фармасьютикал Ко., Лтд. Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения
EP3310786B1 (en) 2015-06-16 2021-03-03 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
EP3350183B1 (en) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201817731A (zh) * 2016-09-29 2018-05-16 日商第一三共股份有限公司 ［２－（１－甲基－１ｈ－吡唑－４－基）－６－（ 啉－４－基）－９ｈ－嘌呤－８－基］［４－（ 啉－４－基）哌啶－１－基］甲酮及其製藥上容許鹽之結晶
KR102399639B1 (ko) 2016-12-02 2022-05-18 다이이찌 산쿄 가부시키가이샤 신규 엔도-β-N-아세틸글루코사미니다아제
SG11202103118PA (en) * 2018-09-27 2021-04-29 Shanghai Yingli Pharmaceutical Co Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
AR120173A1 (es) * 2019-10-09 2022-02-02 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
CN111875606B (zh) * 2020-07-20 2023-04-07 武汉工程大学 一种基于虚拟对接获得的嘌呤类化合物及其制备方法和应用
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN117777134B (zh) * 2022-12-19 2025-02-25 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016378A (en) 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
WO2003022274A2 (en) 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
WO2003031406A2 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
AU2002357295A1 (en) * 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004021979A2 (en) 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
TW200510394A (en) 2003-05-29 2005-03-16 Synta Pharmaceuticals Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
CL2007001166A1 (es) * 2006-04-26 2008-01-25 Piramed Ltd Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
NZ579248A (en) * 2007-03-28 2011-08-26 Neurosearch As Purinyl derivatives and their use as potassium channel modulators
US20100152210A1 (en) 2007-03-28 2010-06-17 Neuro Search A/S/ Purinyl derivatives and their use as potassium channel modulators
CN101835779B (zh) * 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8754080B2 (en) * 2009-04-03 2014-06-17 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (S) inhibitors
SG182247A1 (en) * 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG175708A1 (en) * 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN102711766B (zh) * 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
CA2802808A1 (en) * 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use

Also Published As

Publication number Publication date
ZA201007524B (en) 2012-01-25
US20090318411A1 (en) 2009-12-24
RU2509081C2 (ru) 2014-03-10
CN102105474B (zh) 2014-01-08
BRPI0909614A2 (pt) 2015-09-22
CA2721851A1 (en) 2009-12-03
EP2279188B1 (en) 2015-01-28
US20120135988A1 (en) 2012-05-31
WO2009146406A1 (en) 2009-12-03
AU2009251291A1 (en) 2009-12-03
EP2279188A1 (en) 2011-02-02
AU2009251291B2 (en) 2013-05-02
US8445487B2 (en) 2013-05-21
MX2010012583A (es) 2011-02-24
US8158624B2 (en) 2012-04-17
CN102105474A (zh) 2011-06-22
JP2011521968A (ja) 2011-07-28
KR20110042153A (ko) 2011-04-25
RU2010154428A (ru) 2012-07-10
IL208838A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
ES2533788T3 (es) Compuestos inhibidores de PI3K de tipo purina y métodos de uso
KR101873672B1 (ko) Ｉｄｏ１ 억제제로서 사용하기 위한 피롤리딘-２,５-디온 유도체, 제약 조성물 및 방법
ES2644724T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
ES2360933T3 (es) Derivados de heteroarilo condensados.
AU2012327210B2 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
ES2882797T3 (es) Inhibidores de dihidroorotato deshidrogenasa
JP2017505346A (ja) 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法
ES2543567T3 (es) Métodos de utilización de inhibidores de ALK
EP2521549B1 (en) Therapeutic compounds and related methods of use
CA2729725C (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
CA2681250A1 (en) Chemical compounds
EP3119763A1 (en) Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
ES2875737T3 (es) Derivados de 2-fenil-3H-imidazo[4,5-b]piridina útiles como inhibidores de la actividad tirosina quinasa de ROR1 de mamíferos
AR066659A1 (es) Derivados de espiroindolinona
JP2011507851A (ja) Ｒｈｏキナーゼインヒビターとしてのベンゾイミダゾールおよびアナログ
ES2558608T3 (es) Derivados hetero-bicíclicos como inhibidores del VHC
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
AR084401A1 (es) COMBINACION DEL COMPUESTO GlyT1 CON ANTIPSICOTICOS
KR20100051814A (ko) Ｇｐｒ１１９ ｇ 단백질-커플링된 수용체의 조절 방법 및 선택된 화합물
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
RU2012134306A (ru) Азотосодержащие производные гетероарилов
ES2820553T3 (es) Compuesto y composición farmacéutica para trastorno neuropsicológico o tumor maligno
AR085637A1 (es) Derivados de pirido[2,3-b]pirazina
US20230278964A1 (en) 2,4-diaminoquinazoline derivatives and medical uses thereof
AU2013358876B2 (en) Methods and compositions for inhibiting CNKSR1